264 related articles for article (PubMed ID: 15899610)
1. [Assessment of HER2 status in breast cancer].
Penault-Llorca F; Cayre A
Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
[TBL] [Abstract][Full Text] [Related]
2. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.
Chorn N
Oncol Nurs Forum; 2006 Nov; 33(2):265-72. PubMed ID: 16518442
[TBL] [Abstract][Full Text] [Related]
3. HER2 testing and correlation with efficacy of trastuzumab therapy.
Fornier M; Risio M; Van Poznak C; Seidman A
Oncology (Williston Park); 2002 Oct; 16(10):1340-8, 1351-2; discussion 1352, 1355-8. PubMed ID: 12435204
[TBL] [Abstract][Full Text] [Related]
4. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
Hofmann M; Stoss O; Gaiser T; Kneitz H; Heinmöller P; Gutjahr T; Kaufmann M; Henkel T; Rüschoff J
J Clin Pathol; 2008 Jan; 61(1):89-94. PubMed ID: 17412870
[TBL] [Abstract][Full Text] [Related]
5. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.
Lee JA; Shaheen M; Walke T; Daly M
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):325-41. PubMed ID: 21671702
[TBL] [Abstract][Full Text] [Related]
6. Saving lives with accurate HER2 testing.
Ross JS
Am J Clin Pathol; 2010 Aug; 134(2):183-4. PubMed ID: 20660318
[No Abstract] [Full Text] [Related]
7. Current perspectives on HER2 testing: a review of national testing guidelines.
Bilous M; Dowsett M; Hanna W; Isola J; Lebeau A; Moreno A; Penault-Llorca F; Rüschoff J; Tomasic G; van de Vijver M
Mod Pathol; 2003 Feb; 16(2):173-82. PubMed ID: 12591971
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab administration associated with change in HER2 status.
Dawood S; Resetkova E; Gonzalez-Angulo AM
Clin Breast Cancer; 2008 Aug; 8(4):366-9. PubMed ID: 18757266
[TBL] [Abstract][Full Text] [Related]
9. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
Blank PR; Schwenkglenks M; Moch H; Szucs TD
Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
Ross JS
Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168
[TBL] [Abstract][Full Text] [Related]
11. Recent trends of HER-2 testing and trastuzumab therapy for breast cancer.
Kurosumi M
Breast Cancer; 2009; 16(4):284-7. PubMed ID: 19657709
[TBL] [Abstract][Full Text] [Related]
12. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
[TBL] [Abstract][Full Text] [Related]
13. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.
Wilking U; Karlsson E; Skoog L; Hatschek T; Lidbrink E; Elmberger G; Johansson H; Lindström L; Bergh J
Breast Cancer Res Treat; 2011 Jan; 125(2):553-61. PubMed ID: 20628810
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.
Desmedt C; Sperinde J; Piette F; Huang W; Jin X; Tan Y; Durbecq V; Larsimont D; Giuliani R; Chappey C; Buyse M; Winslow J; Piccart M; Sotiriou C; Petropoulos C; Bates M
Diagn Mol Pathol; 2009 Mar; 18(1):22-9. PubMed ID: 19214112
[TBL] [Abstract][Full Text] [Related]
15. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive value of HER2/neu oncogene in breast cancer.
Masood S; Bui MM
Microsc Res Tech; 2002 Oct; 59(2):102-8. PubMed ID: 12373720
[TBL] [Abstract][Full Text] [Related]
17. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
18. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
Carney WP
IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
20. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
Reddy JC; Reimann JD; Anderson SM; Klein PM
Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
